Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
diffuse large B-cell lymphoma (DLBCL)
Biotech
Regeneron seeks clarity on confirmatory trials after FDA hurdle
Regeneron's Andres Sirulnik says blood cancer medicine odronextamab enrollment is going fine, days after FDA rejection.
Annalee Armstrong
Mar 29, 2024 5:00am
ASH: Regeneron’s near-approval bispecific shines again
Dec 11, 2023 5:25am
Cancer biotech IMV hunts for a deal as its cash clock ticks down
Mar 16, 2023 8:28am
ASH: Regeneron lymphoma med scores but safety muffles excitement
Dec 12, 2022 5:30pm
ASH: Regeneron readies bispecific data—but deaths cast shadow
Dec 12, 2022 7:30am
IMV drops 3rd of staff in refocus on lead oncology asset
Sep 15, 2022 9:45am